Cicactyl from Carob Gum: A New Natural Active That Speeds Skin Healing and Barrier Repair

Key Highlights:
Introduction
From carob gum to Cicactyl: composition and sourcing
How Cicactyl is said to act: the four healing stages
Existing scientific rationale for galactomannans in skin repair
Clinical and cosmetic applications: where Cicactyl fits
Formulation implications: practical notes for chemists
Safety profile and regulatory notes
Comparison with established healing actives
Designing robust performance trials for healing claims
Packaging, claims and communication strategies
Market context: why now for plant-derived healing actives?
Practical application scenarios and case studies (illustrative)
Limitations and research gaps
Integration into broader product portfolios
Best practices for claims substantiation and labeling
What clinicians and formulators should ask next
FAQ

Key Highlights:

Cicactyl, a 100% natural powder derived from carob (Ceratonia siliqua) gum and formulated by Silab Softcare, is presented as an active ingredient that accelerates skin healing by acting on granulation, vascularization, re-epithelialization and inflammation.
The ingredient (INCI: Galactomannan & Maltodextrin) is preservative-free, intended for low-dose use (0.05–1%), and positioned for healing cosmetic and dermo-cosmetic applications for adults, pregnant and breastfeeding women, and infants.

Introduction

Wound care and barrier repair have moved from clinical settings into mainstream skincare as consumers and practitioners demand gentler, evidence-driven actives that support recovery without harsh additives. Cicactyl, a new natural active extracted from carob gum and developed by Silab Softcare, aims to meet that need. Marketed as a preservative-free powder that supports multiple stages of healing, Cicactyl targets erythema, dryness and scabbing from the first applications. The product arrives amid intensified interest in plant-derived polysaccharides and minimal-ingredient formulations for fragile and compromised skin. Understanding what Cicactyl is, how it works, where it fits among existing options and how formulators should approach it matters for brands, clinicians and consumers alike.

From carob gum to Cicactyl: composition and sourcing

Cicactyl’s INCI—Galactomannan & Maltodextrin—encapsulates the ingredient’s two core components. Galactomannans are long-chain polysaccharides abundant in carob (Ceratonia siliqua) seeds and widely used in food and cosmetics as thickeners and stabilizers. Maltodextrin serves as a low-molecular-weight carbohydrate carrier that improves handling, dispersibility and product stability.

Carob has a long material history: the seeds and gums derived from the pod are used across industries for their rheological properties and relative inertness. Turning carob gum into a cosmetic active requires targeted extraction and fractionation to concentrate bioactive polysaccharide fractions with favorable molecular weights and functional groups. Silab Softcare has positioned Cicactyl as the result of such processing: a natural, preservative-free powder that retains the mucoadhesive, film-forming and humectant characteristics associated with galactomannans while leveraging maltodextrin for formulation ease.

Sourcing considerations matter for brands: traceability, agricultural practices, and extraction methods affect both the environmental footprint and the biochemical profile of the final material. The ISO 16128 designation noted by Silab classifies Cicactyl as a natural ingredient under industry standards that quantify natural and organic content. That classification supports marketing claims to consumers seeking plant-based, non-synthetic options.

How Cicactyl is said to act: the four healing stages

Silab describes Cicactyl as accelerating healing through four key stages: granulation tissue formation, vascularization, wound re-epithelialization and reduction of inflammation. Those targets map onto established phases of the cutaneous healing process:

Hemostasis and inflammation: Immediately after injury, clotting and immune cell recruitment contain damage and remove debris. Excessive inflammation delays healing and increases scarring risk.
Proliferation (granulation and vascularization): Fibroblasts lay down extracellular matrix and new capillaries grow into the wound bed to supply nutrients—forming granulation tissue that will support re-epithelialization.
Re-epithelialization: Keratinocytes migrate and proliferate to close the surface defect and restore barrier function.
Remodeling: Collagen reorganizes and tensile strength increases over weeks to months.

A single ingredient able to favorably influence multiple stages would be strategically valuable. Cicactyl’s galactomannan fraction plausibly contributes through several mechanisms that align with these processes:

Moisture retention and film formation: Polysaccharides often form hydrophilic films that maintain a humid wound microenvironment. Controlled moisture supports keratinocyte migration and reduces scab formation.
Barrier protection and bioadhesion: Mucoadhesive properties help the active remain in contact with damaged skin, extending local activity and reducing transepidermal water loss (TEWL).
Modulation of inflammation: Certain polysaccharide fractions can interact with immune cells and modulate cytokine release; such interactions may reduce excessive inflammatory signals that impede progress.
Substrate and matrix effects: Polysaccharides can create a provisional extracellular scaffold conducive to fibroblast activity and neovascularization.

Maltodextrin’s role extends beyond being an inert carrier. In wound care and topical science, low-molecular-weight carbohydrates can serve as osmotic modulators, energetic substrates for repair processes and formulation stabilizers that improve the delivery profile of larger polysaccharides.

Silab’s public description focuses on clinically relevant endpoints—reduction of erythema, dryness and scabs from early use—without providing granular trial data in the source material. Those endpoints reflect outcomes most visible to consumers and frequently used in split-face or vehicle-controlled studies. The claim that Cicactyl acts on vascularization and granulation suggests underlying histological or biomarker evidence, which would be relevant for clinicians and formulators seeking to substantiate performance claims.

Existing scientific rationale for galactomannans in skin repair

Galactomannans are not new to biomedical science. A brief overview of relevant properties helps place Cicactyl in context:

Hydrophilicity and gel formation: Galactomannans readily hydrate and form viscous solutions or gels depending on concentration and polymer structure. Hydration maintains a moist wound bed, which reduces scab formation and supports keratinocyte migration—two of the outcomes Cicactyl is reported to improve.
Film-forming and protective qualities: These polysaccharides can create semi-occlusive films that protect fragile skin from mechanical insult and external irritants while allowing gas exchange.
Biocompatibility: Plant-derived polysaccharides typically have low toxicity and a low incidence of sensitization compared with some synthetic polymers, which makes them attractive for infant and pregnancy-safe products.
Interaction with cells and extracellular matrix: While mechanisms are still under investigation, polysaccharides can influence fibroblast behavior and collagen deposition indirectly by altering the wound microenvironment and directly through receptor-mediated pathways in some cases.

These properties have supported the use of other polysaccharide-based materials in wound dressings, hydrogels and topical vehicles. Cicactyl’s novelty lies in the specific galactomannan fraction selected, the processing that yields a stable, preservative-free powder, and the combination with maltodextrin.

Clinical and cosmetic applications: where Cicactyl fits

Silab recommends Cicactyl for healing cosmetic and dermo-cosmetic facial and body care products, including applications for adults (pregnant and breastfeeding) and infants. The designation implies a broad set of potential uses:

Post-procedure care: After in-office dermatological procedures—laser resurfacing, microneedling, chemical peels—skin benefits from supportive actives that reduce erythema and redness, limit crusting and accelerate re-epithelialization. An ingredient that speeds these endpoints without sensitizing or adding preservatives is attractive to clinics and post-care lines.
Everyday barrier support for fragile skin: Conditions characterized by impaired barrier function—eczema-prone skin, irritant dermatitis and chronically dry skin—require agents that reduce TEWL, soothe irritation and facilitate repair. Cicactyl’s film-forming and humectant properties align with these needs.
Infant skincare: Newborn and infant skin has thin stratum corneum and immature barrier function. Products for diaper-area care, mild excoriations and dry patches require gentle actives with minimal allergenicity and proven safety. Cicactyl’s preservative-free, natural profile increases its relevance here.
Scar-minimizing or supportive products: By promoting balanced granulation and re-epithelialization, the ingredient may be useful in formulations designed to support optimal healing to reduce hypertrophic scarring risk.

Brands will be cautious about claim language and regulatory constraints. For over-the-counter cosmetic products, claims must be substantiated and cannot cross into drug claims unless supported by clinical trials demonstrating measurable medical outcomes. Cicactyl’s positioning as a cosmetic/dermo-cosmetic active suggests intent for claims such as “supports skin recovery,” “reduces redness and dryness during skin repair,” or “helps restore the skin barrier,” provided controlled data backs those statements.

Formulation implications: practical notes for chemists

Cicactyl is offered as a preservative-free powder with a recommended usage range of 0.05% to 1%. That low-dose range indicates potency and potential for inclusion in multiple product formats. Formulators should consider the following:

Dispersion and hydration: As a powdered polysaccharide, Cicactyl will require proper dispersion in the aqueous phase with controlled shear. Pre-hydration in a small portion of the batch or slow addition under stirring can prevent clumping.
Vehicle selection: The active’s hydrophilicity favors water-based systems—gels, creams with aqueous phases, serums and sprays. Combining Cicactyl with low levels of humectants (glycerin, hyaluronic acid of defined molecular weight) and mild emollients can enhance immediate skin feel while retaining the active’s film-forming benefits.
pH stability: Polysaccharide function can be pH-sensitive. Formulators should test the active across intended pH ranges used in post-procedure and sensitive-skin products. Acidic or alkaline extremes may affect viscosity and bioadhesion.
Preservation strategy: The ingredient itself is preservative-free. Finished product preservation must be carefully addressed, particularly for emulsions and products with water activity conducive to microbial growth. Options include multi-faceted preservative systems, airless packaging, single-dose formats, or synergistic formulation choices that lower water activity.
Compatibility and sensory: Polysaccharide actives may increase viscosity or alter skin feel. Selecting compatible emulsifiers, rheology modifiers and sensory enhancers ensures consumer acceptability. For post-procedure lines, lightweight, fast-absorbing textures typically perform best.
Stability and shelf-life: Because the active is marketed preservative-free, brands should run accelerated and real-time stability testing for microbial safety and physical-chemical parameters. Packaging that minimizes contamination—airless pumps, tubes with narrow orifices—reduces conservancy demands.

Formulators planning low-concentration uses will want to understand minimum effective dose from Silab’s data and test sensory trade-offs across product matrices. The 0.05–1% range provides flexibility: ultra-light serums may use lower doses while richer balms or occlusive dressings can use higher amounts.

Safety profile and regulatory notes

Silab emphasizes that Cicactyl is free from “harmful or potentially allergenic substances” and suitable for pregnant and breastfeeding women and infants. Safety claims of this type rely on a few components:

Low sensitization potential: Polysaccharides generally display low potential for allergic sensitization compared with botanical extracts that contain secondary metabolites. Still, patch testing and safety-in-use data remain essential.
Preservative-free designation: Not containing preservatives reduces the risk of preservative-related contact dermatitis. Yet finished product preservation requires attention to protect users from microbial contamination.
ISO 16128 compliance: ISO 16128 provides a framework for defining natural and organic content in cosmetic products. Cicactyl's classification supports natural-ingredient marketing claims under widely recognized metrics.

Regulatory positioning will vary by market. Cosmetic claims in the EU and US are subject to differing standards—claims implying healing or treatment can trigger classification as a medicinal product or drug in some jurisdictions. Brands must carefully word marketing material and maintain technical substantiation. For medical or wound-care applications beyond cosmetics, clinical trials and medical device or drug registration pathways would be necessary.

Comparison with established healing actives

The skincare market already contains a range of documented skin-repair actives. Comparing Cicactyl against these clarifies its unique selling points:

Panthenol (provitamin B5): Known for humectant and hydrating effects and for supporting re-epithelialization. Cicactyl brings film-forming polysaccharide benefits that can complement panthenol’s humectancy.
Hyaluronic acid: Strong water-holding capacity and roles in tissue hydration and cell signaling. HA can be used together with Cicactyl to increase moisture retention and improve skin feel.
Allantoin: Soothing, keratolytic and promotes cell proliferation. Cicactyl’s potential to support granulation and vascularization differentiates it mechanistically.
Centella asiatica extracts (asiaticoside, madecassoside): Promotes collagen synthesis and supports wound healing. Centella’s triterpenoids act on collagen pathways; Cicactyl operates more through moisture management and provisional matrix effects.
Silicone-based scar sheets: Provide occlusion and pressure that favorably influence scar remodeling. Cicactyl’s film-forming properties offer semi-occlusion but not the mechanical effects of silicone sheeting.

A key advantage for Cicactyl is its formulation as a preservative-free, natural powder at low use levels combined with a safety profile that situates it for sensitive populations. In product design, Cicactyl is most likely to be positioned alongside other supportive actives that together address moisture balance, anti-inflammatory needs and tissue repair.

Designing robust performance trials for healing claims

Brands and clinicians evaluating Cicactyl—or any new healing active—need rigorous testing to substantiate claims. Practical trial designs include:

Split-area randomized controlled trials: For facial or limb lesions, applying product vs. vehicle on contralateral sites limits inter-subject variability. Primary outcomes include erythema scoring (visual and instrumental), TEWL, hydration, and visual healing endpoints.
Post-procedure cohort trials: Patients receiving standard-of-care procedures (e.g., fractional laser, microneedling) apply the active formulation vs. standard aftercare to compare recovery timelines, pain scores, crusting incidence and time to re-epithelialization.
Histological and biomarker studies: In preclinical or surgical contexts, biopsy samples can assess granulation tissue formation, neovascularization markers (VEGF, CD31) and inflammatory cytokine profiles to document mode-of-action claims.
Infant and sensitive-skin studies: For products intended for infants and pregnant women, safety and tolerance studies with dermatological scoring and parent-reported outcomes are essential.
Consumer perception and sensory trials: Because early perceived effects (reduced redness, less tightness) drive adoption, incorporate validated subjective metrics alongside objective measures.

Endpoints should be pre-specified, and studies should include adequate sample sizes to detect clinically meaningful differences. Brands seeking stronger claims may pursue randomized, double-blind, vehicle-controlled trials with independent dermatological assessments.

Packaging, claims and communication strategies

Translating Cicactyl’s technical attributes into consumer-facing claims requires careful messaging. Points to highlight without overstepping regulatory boundaries include:

Natural origin and ISO 16128 classification: Consumers respond strongly to natural-designation messaging, especially for sensitive-skin products.
Preservative-free ingredient profile: The ingredient itself is preservative-free; brands should clarify whether finished products are preserved and why that choice was made.
Low allergenicity and suitability for fragile skin: Phrases such as “formulated for fragile and sensitive skin” work when supported by tolerance data.
Functional claims: “Supports skin recovery,” “soothes redness and reduces dryness during skin repair,” or “helps limit scab formation” are acceptable when backed by clinical evidence. Avoid therapeutic or drug claims unless supported by appropriate clinical trials and regulatory approvals.

Packaging choices—airless pumps, individually sealed sachets or single-use ampoules—can reinforce a product’s suitability for post-procedure and infant applications while minimizing contamination risk and enabling minimal-preservative strategies.

Market context: why now for plant-derived healing actives?

Several market forces favor the launch of an ingredient like Cicactyl:

Consumer demand for natural, minimal-ingredient skincare: A shift toward simple, plant-based formulations with clear ingredient stories supports new polysaccharide actives.
Growth of at-home and in-clinic post-procedure care: As cosmetic procedures grow in number and diversity, the need for effective aftercare products increases.
Heightened awareness of barrier health: The pandemic-era focus on skin damage from masks and frequent handwashing heightened consumer interest in barrier repair products.
Increased scrutiny of preservatives and sensitizers: Consumers and clinicians prefer formulations that limit known irritants, raising appeal for preservative-free active ingredients.

Silab Softcare situates Cicactyl within these trends by emphasizing its natural pedigree and targeted action for fragile skin. The division’s focus on natural actives for dermatological conditions gives Cicactyl an institutional backing that matters to both private-label brands and clinical product lines.

Practical application scenarios and case studies (illustrative)

The following scenarios illustrate how Cicactyl could be integrated into product strategies. These are hypothetical applications to demonstrate practical fit rather than results from Silab trials.

Post-laser recovery serum: A water-based serum containing 0.5% Cicactyl, panthenol and low-molecular-weight hyaluronic acid. The serum is applied twice daily after initial wound closure to reduce residual redness and dryness and to support re-epithelialization.
Infant barrier balm: A low-dose Cicactyl formula combined with zinc oxide and mild emollients for diaper-area protection. Packaging in a tube reduces contamination risk and underscores safety for infant use.
Clinic aftercare gel: A sterile, single-use ampoule containing Cicactyl and soothing botanical glycosides for immediate post-procedure application. The single-dose format supports microbial safety and clinical convenience.
Atopic-prone skin cream: A cream for adults with eczema-prone skin combining Cicactyl at 1% with colloidal oatmeal and ceramides to improve hydration and reduce flare-associated drying and scabbing.

Each scenario requires stability and microbial testing, and claims must align with clinical substantiation and regulatory frameworks applicable to the market where products will be sold.

Limitations and research gaps

While Cicactyl’s positioning is compelling, several areas warrant further investigation:

Mechanistic clarity: Direct evidence delineating how the specific galactomannan fraction modulates angiogenesis, fibroblast behavior and keratinocyte migration would strengthen mode-of-action claims.
Comparative efficacy: Head-to-head trials comparing Cicactyl to well-established actives (panthenol, hyaluronic acid, centella extracts) would help formulators choose complementary or replacement strategies.
Long-term outcomes: Data on scar quality, tensile strength of repaired tissue and remodeling outcomes would broaden medical applications.
Microbiome interactions: Understanding how polysaccharide films affect the skin microbiome during healing could inform product pairings and preservative strategies.
Pediatric-specific studies: Controlled safety and efficacy trials in infant populations provide critical reassurance for clinicians and parents.

Silab or independent investigators can address these gaps through targeted preclinical studies and well-designed clinical trials.

Integration into broader product portfolios

For brands building sensitive-skin or post-procedure lines, Cicactyl can function as a core differentiator or a complementary ingredient. Integration strategies include:

Flagship healing product: Build a clinically validated serum or gel with Cicactyl as the hero active and develop claims supported by controlled trials.
Multi-step regimens: Position Cicactyl in the recovery step of a multi-product regimen—cleanse, protect, repair—with formulations tailored to specific use cases (e.g., post-procedure vs. everyday barrier repair).
Co-branding with clinics: Collaboration with dermatology clinics for co-branded post-care kits can accelerate adoption and provide real-world evidence from patient cohorts.
Education-driven marketing: Provide clear materials explaining the four healing stages Cicactyl targets and why polysaccharide-based repair differs from purely anti-inflammatory or hydrating strategies.

These approaches require investment in clinical proof points and user education but can yield durable brand positioning in the sensitive-skin segment.

Best practices for claims substantiation and labeling

To avoid regulatory pitfalls and maximize consumer trust, brands working with Cicactyl should:

Obtain and publish clinical data supporting specific claims: Avoid vague language and ensure endpoints are meaningful to consumers (visual redness reduction, time to re-epithelialization, TEWL improvement).
Be transparent about formulation preservation: If finished products contain preservatives, disclose that clearly while explaining why preservation is necessary for safety.
Use accurate INCI listing: Galactomannan & Maltodextrin should appear on labels as required.
Tailor claims to jurisdictional rules: Regulatory bodies differ in their treatment of “healing” or “repair” claims. Work with legal and regulatory experts to align marketing language.
Provide usage guidance for sensitive populations: Clear instructions reduce misuse, particularly for infants and post-procedure patients.

Adhesion to these practices reduces risk and fosters credibility among healthcare professionals and informed consumers.

What clinicians and formulators should ask next

Clinicians evaluating Cicactyl for incorporation into aftercare protocols or formulators considering the active for product development should seek the following information from the supplier:

Full composition and molecular-weight distribution of the galactomannan fraction.
Data on dose-response relationships and minimum effective concentration.
Stability and compatibility testing results across common formulation systems.
Clinical study reports—including methodology, endpoints and safety observations—relevant to proposed claims.
Recommended packaging and preservation guidelines for specific product formats.

Access to robust technical documentation accelerates responsible product development and clinical adoption.

FAQ

Q: What is Cicactyl and where does it come from? A: Cicactyl is a natural active ingredient derived from carob (Ceratonia siliqua) gum, composed principally of galactomannan and maltodextrin (INCI: Galactomannan & Maltodextrin). It is presented as a preservative-free powder for topical cosmetic and dermo-cosmetic applications.

Q: How does Cicactyl help with skin healing? A: According to Silab, Cicactyl accelerates healing by supporting four stages of tissue repair: granulation tissue formation, vascularization, wound re-epithelialization and the reduction of inflammation. Mechanistically, the galactomannan fraction can create a hydrophilic film, retain moisture, and provide a provisional matrix that supports cell migration and reduces scab formation, while maltodextrin aids formulation and may act as a bioavailable carbohydrate substrate.

Q: Is Cicactyl safe for infants and pregnant or breastfeeding women? A: Silab positions Cicactyl for use in products intended for adults—including pregnant and breastfeeding women—and infants. Plant-derived polysaccharides typically have low allergenicity; however, brands must conduct safety-in-use testing on finished products and adhere to regulatory requirements for claims and labeling.

Q: At what concentrations is Cicactyl recommended? A: The supplier recommends use levels ranging from 0.05% to 1%. Final formulation testing will determine the optimal concentration for efficacy and sensory performance in a given product matrix.

Q: Does Cicactyl replace preservatives in finished products? A: No. Cicactyl itself is preservative-free, but finished water-containing products generally require preservation to ensure microbial safety. Brands can pursue reduced-preservative strategies or protective packaging, but microbial safety testing remains essential.

Q: What product types are best suited to include Cicactyl? A: Cicactyl fits a range of formats: serums, gels, creams, balms, and single-use post-procedure ampoules. Its hydrophilic and film-forming properties make it suitable for post-procedure aftercare, infant barrier products and formulations targeting fragile or compromised skin.

Q: How should brands substantiate claims about Cicactyl? A: Controlled clinical studies, such as split-face randomized trials, post-procedure cohort trials, and tolerance studies in target populations (infants, sensitive-skin subjects), provide the evidence foundation for claims. Objective measures—TEWL, erythema instrumentation, time-to-closure—and standardized visual scoring are recommended endpoints.

Q: How does Cicactyl compare to existing actives like panthenol or hyaluronic acid? A: Cicactyl brings polysaccharide-driven film formation and provisional matrix effects that complement humectants (hyaluronic acid) and keratolytics/soothers (panthenol, allantoin). It is best viewed as part of a multi-ingredient strategy that combines moisture retention, anti-inflammatory support and barrier restoration.

Q: What are the next research priorities for Cicactyl? A: Areas for further study include mechanistic work on cellular pathways impacted by the galactomannan fraction, head-to-head efficacy comparisons with established actives, long-term remodeling and scar quality outcomes, and microbiome interaction studies during healing.

Q: Where does Cicactyl fit within market trends? A: Cicactyl responds to growing demand for natural, minimal-ingredient actives that support skin barrier health and post-procedure recovery. Its preservative-free profile and suitability for sensitive populations align with current consumer and clinic-driven trends toward gentler, plant-derived solutions.

This profile of Cicactyl highlights why plant-derived polysaccharide actives remain attractive to formulators and clinicians seeking to support skin repair with fewer irritants. For brands, the ingredient offers a clear narrative and technical promise—provided that clinical substantiation and careful formulation practices accompany product development.